CSL launches Cinryze rival Haegarda despite Shire's best efforts—at a big discount, too
admin 20th July 2017 Uncategorised 0Shire fought hard to protect hereditary angioedema med Cinryze from new competition, but CSL is launching its new rival Haegarda right now—and the Australian company has its eye on Shire’s market share.
More: CSL launches Cinryze rival Haegarda despite Shire's best efforts—at a big discount, too
Source: fierce